XML 20 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 23,690 $ 32,154
Marketable securities 33,936 37,072
Prepaid and other current assets 3,797 2,650
Total current assets 61,423 71,876
Property and equipment, net 233 296
Finite-Lived Intangible Assets, Net 299 334
Other assets 410 528
Total assets 62,365 73,034
Liabilities    
Accounts payable 775 2,655
Accrued liabilities 3,581 3,728
Total current liabilities 4,356 6,383
Other long-term liabilities 295 327
Total liabilities 4,651 6,710
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,133,095 and 7,866,799 shares at June 30, 2023 and December 31, 2022, respectively; and outstanding, 8,132,357 and 7,866,061 shares at June 30, 2023 and December 31, 2022, respectively 8 8
Additional paid-in capital 576,173 574,548
Treasury stock, at cost; 738 shares at June 30, 2023 and December 31, 2022 (708) (708)
Accumulated deficit (517,455) (507,241)
Accumulated other comprehensive loss (50) (29)
Total Lisata Therapeutics, Inc. stockholders' equity 57,968 66,578
Non-controlling interests (254) (254)
Total stockholders' equity 57,714 66,324
Total liabilities, non-controlling interests and stockholders' equity $ 62,365 $ 73,034